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Abstract
Spongiform encephalopathies have been reported to be transmitted by blood transfusion even prior to the clinical onset.
Experimental AA-amyloidosis shows similarities with prion disease and amyloid-containing organ-extracts can prime a
recipient for the disease. In this systemic form of amyloidosis N-terminal fragments of the acute-phase reactant
apolipoprotein serum amyloid A are the main amyloid protein. Initial amyloid deposits appear in the perifollicular region of
the spleen, followed by deposits in the liver. We used the established murine model and induced AA-amyloidosis in NMRI
mice by intravenous injections of purified amyloid fibrils (‘amyloid enhancing factor’) combined with inflammatory
challenge (silver nitrate subcutaneously). Blood plasma and peripheral blood monocytes were isolated, sonicated and re-
injected into new recipients followed by an inflammatory challenge during a three week period. When the animals were
sacrificed presence of amyloid was analyzed in spleen sections after Congo red staining. Our result shows that some of the
peripheral blood monocytes, isolated from animals with detectable amyloid, contained amyloid-seed that primed for AA-
amyloid. The seeding material seems to have been phagocytosed by the cells since the AA-precursor (SAA1) was found not
be expressed by the monocytes. Plasma recovered from mice with AA amyloidosis lacked seeding capacity. Amyloid
enhancing activity can reside in monocytes recovered from mice with AA-amyloidosis and in a prion-like way trigger
amyloid formation in conjunction with an inflammatory disorder. Human AA-amyloidosis resembles the murine form and
every individual is expected to be exposed to conditions that initiate production of the acute-phase reactant. The
monocyte-transfer mechanism should be eligible for the human disease and we point out blood transfusion as a putative
route for transfer of amyloidosis.
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Introduction
Amyloidosis is a heterogeneous group of protein conformational
diseases, characterized by accumulation of protein fibrils with
distinctive b-pleated structure in different organs and tissues.
Hitherto, more than 25 different proteins have been isolated and
characterised from amyloid deposits [1]. The mechanisms leading
to b-pleated sheet conformation of natural soluble precursor
proteins and the propagation of amyloid fibrils are unknown. AA-
(reactive) amyloidosis that occurs in patients with rheumatoid
arthritis and other chronic inflammatory diseases, results from a
sustained elevation of the precursor, apolipoprotein serum amyloid
A (SAA). SAA is an acute phase reactant produced mainly by the
hepatocytes under regulation by interleukin (IL)-1, IL-6, and
tumour necrosis factor [2,3]. N-terminal fragments (protein AA) of
SAA make up the amyloid fibril [4–7]. It is a systemic disease and
AA amyloid deposits are present throughout the body, but
proteinuria is often the first clinical manifestation. AA amyloidosis
can be induced experimentally in susceptible mouse strains by
inflammatory stimuli that result in a .1,000-fold increase in SAA
plasma concentration. Several isoforms of acute phase SAA are
known [8], but only SAA1 (former SAA2) serves as a precursor of
amyloid fibrils in mice [9].
Development of experimental AA amyloidosis is a biphasic
process with a long predeposition phase under which protein
aggregates are formed, and a second phase characterized by fibril
propagation [10].The time for development of amyloidosis is
shortened from several weeks to days in mice after injection of or
feeding with extracts from amyloid-laden tissue [11–14]. The
active component is referred to as ‘amyloid enhancing factor’
(AEF) and has been identified to be the AA fibril itself [13,15]. In
the mouse model, the primary site for amyloid deposition is the
spleen followed by deposits in liver, and if the kidneys are engaged
this happens at much later time point. However, amyloid at this
latter site has been suggested to originate from redistribution of
amyloid rather than being recently formed [16].The same
distribution pattern is seen both with and without acceleration of
amyloidosis by AEF [17]. Rather than being initiated at various
sites, this spreading most likely occurs by seeding with preformed
amyloid fibrils. How these reach different sites in the body is
unknown but theoretically seed can be transferred by blood
plasma or by cells. In animal studies, AA-amyloidosis displays
great similarity with transmissible spongiform encephalitis (TSE),
because both diseases can be induced or accelerated by
introduction of aggregates of misfolded proteins and can be
transferred between subjects [13,18–22]. It has been shown that
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prions were reported to be transmitted by animal blood
transfusion even prior to the clinical onset of the disease [23].
Herein, we have analysed if blood cells or plasma recovered
from mice with AA-amyloidosis house amyloid-seed that can
prime for the disease when transferred to a new animal. We have
used the experimental mouse model for AA-amyloidosis and show
that monocytes can transfer amyloid-seed but that this is not true
for plasma. We also show that the monocytes do not express
SAA1, the precursor-protein for AA-amyloid, but they contain
intracellular immunoreactivity specific for the protein. The
findings indicate that amyloid is phagocytosed by the monocytes
and remains intracellularly in a form that retains its seeding
activity. In conjunction with inflammation extracellular exposure
of this AA-seed triggers development of AA-amyloidosis.
Results
Analysis of AEF activity in plasma and peripheral blood
monocytes
At first, plasma from amyloidotic mice was analysed for AEF
activity. Mice in group A that received AEF and three AgNO3
injections developed moderate AA-amyloidosis as quantified from
Congo red stained spleen sections. Amyloid did not develop in
group B mice that received a single injection of AEF without the
subsequent inflammatory stimuli or in untreated group C mice
(Table 1). Plasma was recovered from mice in group A–C in which
the animals were sacrificed on day 16, and after sonication re-
injected into new recipient mice (groups D–F, respectively). These
mice received inflammatory stimuli day 1,7,14 and were sacrificed
day 16. Spleen sections were stained for amyloid with Congo red
and analysed in polarized light. Amyloid was not detected in the
spleen of any of the mice in groups D–F. The absence of amyloid
in group D mice shows that plasma collected from animals with
AA-amyloid does not reside AEF activity and can not trigger
development of the disease during chronic inflammation. The
absence of amyloid in group D and E mice shows that the amount
of AEF given to mice in group A and B is by itself not sufficient for
transfer. As expected, mice injected with plasma isolated from
untreated animals also lacked seeding activity. Taken together
these results show that AA-fibrils don’t exist free in circulation and
plasma does not serve as a transmitter of AA-amyloid (Table 1).
The study continued with analysis of the possibility that
peripheral blood monocytes carry amyloid seeds. Profound
amounts of amyloid developed in spleen of group G mice after
given AEF and 5 weekly AgNO3 injections. Isolated and sonicated
peripheral blood monocytes from group G mice were re-injected
into new mice (H1-9). Inflammatory stimuli were given to mice in
the groups H1-8. These groups varied in size and contained 5–8
animals (Table 2). After Congo red staining, amyloid deposits were
detected in 19/48 (40%) of the recipient mice. The amyloid was
present in the perifollicular area of the white pulp, and ranged
from traces up to moderate amount (1+ to 3+) (Figure 1). The
percentage of affected animals differed between groups and in
group H2 all mice developed amyloid while this was absent in
mice from group H5 and H7 (Table 3). The five animals in group
H9 received monocytes isolated from G9 without the concomitant
inflammatory stimuli (group H9), and no amyloid developed.
Table 1. Analysis of AEF activity in plasma from mice with AA-amyloidosis.
Treatment of donor mice Recipient mice
Group AEF AgNO3
No. of mice with
amyloid/total no. of mice Amyloid grade Group
No. of mice with
amyloid/total no. of mice
A ++ 10/10 2+–3+ D 0/20
B + 2 0/11 2 E 0/22
C 22 0/10 2 F 0/10
Mice from group A received AEF and 0.2 ml 1% silver nitrate on day 1 and further injections of silver nitrate on day 7 and 14, mice in group B received AEF day 1a n d
mice in group C were untreated. Animals were sacrificed on day 16. The presence of amyloid was analysed in spleen after Congo red staining and plasma was collected,
sonicated and 0.1 ml was injected i.v. in new mice (groups D–F). These mice received inflammatory stimuli day 1, 7 and 14 and were sacrificed day 16. The presence of
amyloid was analysed in spleen sections after Congo red staining.
doi:10.1371/journal.pone.0003308.t001
Table 2. Analysis of AEF activity in peripheral blood monocytes isolated from mice with AA-amyloid induced by AEF.
Treatment of donor mice Recipient mice
Mouse AEF AgNO3
No. of mice with
amyloid/total no.
of mice Amyloid grade Group
No. of mice with
amyloid/total no.
of mice Amyloid grade
G1–G8 ++ 8/8 4+ H1–8 19/48 1+–3+
G9 ++ 1/1 4+ H9 0/5 2
G10 22 2 H10 0/9 2
AA-amyloid was induced in nine mice (G1–G9) by an i.v. injection of 0.1 ml AEF with concomitant s.c. injection of 0.2 ml 1% silver nitrate day 1, 7, 14, 21 and 28 and the
mice were sacrificed on day 35. The presence of amyloid in the spleen was verified by Congo red staining. Peripheral blood monocytes were isolated, sonicated and re-
introduced into the blood circulation of new groups of healthy mice (H1–H8). These mice received inflammatory stimuli day 1, 7 and 14 and were sacrificed day 16. The
presence of amyloid was analysed in spleen sections after Congo red staining. Mice in group H9 received sonicated monocytes without subsequent inflammatory
stimuli and group H10 received monocytes isolated from untreated mice and subsequent inflammatory stimuli on day 1, 7 and 14 and were sacrificed day 16 (group
H10).
doi:10.1371/journal.pone.0003308.t002
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animals and after sonication injected into nine mice (H10) which
received the concomitant inflammatory stimuli. Also in these mice
amyloid was absent (Table 2). To validate this phenomenon,
peripheral blood monocytes were isolated from the five mice of
group H2 that developed AA-amyloid deposits triggered by
sonicated peripheral blood monocytes and AgNO3 injections. The
isolated monocytes were after sonication reinjected into new
groups of healthy mice (groups J1–J5) and AgNO3 was
administered as before. Indeed, after 16 days amyloid was present
in 80% (12/15) of the animals in group J 1–5. The degree of
amyloid ranged from 1+ to 2+ (Table 4). To study the connection
between amyloid load and transmissibility, we tested AEF-activity
of monocytes isolated from mice injected with regular AEF and
AgNO3 and sacrificed at different intervals. Two minutes was the
shortest studied time point and this was expected to be sufficient to
ensure that AEF has been distributed throughout the body (group
K1). Six hours (group K2) were expected to be sufficient for AEF
to be phagocytosed by monocytes present in circulation. However,
we did not observe any amyloid deposits in mice injected with
monocytes isolated from K1 and K2 (groups L1 and L2,
respectively), Table 5. In mice sacrificed 48 hrs after AEF and
AgNO3 injection (group K3) it was possible to detect traces (1+)o f
amyloid in 3 out of 3 mice, but monocytes isolated from these mice
did not reveal any AEF-activity (group L3). The seeding effect was
first observed in mice from group L4 that received monocytes
isolated from mice sacrificed 7 days after the AEF and AgNO3
injection, group K4. Amyloid was detected in 5 out of 9 mice
(56%) (Table 5).
Isolation of peripheral blood monocytes
Peripheral blood monocytes were isolated from relatively small
volumes of 1 ml blood. With the Ficoll-Paque isolation procedure
granulocytes are expected to be excluded from the white blood
cells that remain on the top of the gradient. During overnight
incubation monocytes are expected to adhere to the plastic
support while most of the lymphocytes should remain in the non-
adherent fraction. Analysis of cells recovered after rinsing and
trypsination revealed an enrichment of monocytes. Comparison of
cytometry analysis of cell isolations before and after overnight
culture shows an enrichment of cells with monocytes appearance
in the latter. The monocyte population of the four different
isolations varied (64615%; mean6SD) (Figure 2A). At high
resolution it was shown that the majority of isolated cells were
monocytes (Figure 2B).
Figure 1. Spleen amyloid deposits stained with Congo red. (A)
The amyloid appears pink and is localized to the perifollicular zone. (B)
The identical area exhibits green birefringence in polarized light.
Amyloid is indicated by arrows.
doi:10.1371/journal.pone.0003308.g001
Table 3. Analysis of AEF activity in peripheral blood
monocytes isolated from mice with AA amyloidosis.
Donor mice Recipient mice
Mouse
Amyloid
grade Group
No. of mice with
amyloid/total no.
of mice
Amyloid
grade
G1 4+ H1 5/7 1+–2+
G2 4+ H2 5/5 1+–3+
G3 4+ H3 4/8 1+–2+
G4 4+ H4 1/6 1+
G5 4+ H5 0/6 2
G6 4+ H6 2/6 1+–2+
G7 4+ H7 0/5 2
G8 4+ H8 2/5 1+–2+
The table presents detailed information on animals in group H 1–8. AA-
amyloidosis was induced by i.v. injection of AEF and 0.2 ml 1% silver nitrate
injections on day 1, 7, 14, 21 and 28. The animals were sacrificed on day 35.
Blood was collected and amyloid was verified in spleen sections after Congo
red staining. Isolated peripheral blood monocytes were injected into new
animals, group H 1–8, and silver nitrate was given day 1, 7 and 14.The animals
were sacrificed day 16 and the presence of amyloid was studied in spleen after
Congo red staining.
doi:10.1371/journal.pone.0003308.t003
Table 4. Analysis of AEF activity in peripheral blood
monocytes isolated from mice with AA amyloid induced by
monocytes isolated from mice with AEF-induced AA amyloid.
Donor mice Recipient mice
Mouse
Amyloid
grade Group
No. of mice with
amyloid/total
no. of mice
Amyloid
grade
H2-1 1+ J1 2/3 1+–2+
H2-2 3+ J2 3/3 1+
H2-3 2+ J3 2/3 1+
H2-4 1+ J4 3/3 1+–2+
H2-5 2+ J5 2/3 2+
Mice in group J received an i.v. injection of monocytes isolated from H2 (1–5)
and a sequential s.c. injection of 0.2 ml 1% silver nitrate day 1, 7 and 14 and
were sacrificed day 16.The presence of amyloid was analyzed in spleen after
Congo red staining.
doi:10.1371/journal.pone.0003308.t004
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AgNO3 injection generates an acute phase response with striking
increase of SAA production within 24 hours. Hepatocytes are the
predominant site for production of SAA 1 and SAA2, but
extrahepatic production occurs at different sites and SAA 3 is
reported to be produced by macrophages and adipocytes. Immuno-
labeling with antiserum produced against isolated mouse amyloid A,
and therefore reactive against SAA 1 and 2, labelled the cytoplasm of
5% of the monocytes isolated from mice with AA-amyloidosis
(Figure 3A). No reactivity was present in monocytes isolated from
mice that were challenged with one AgNO3injection 48 hoursearlier
or from monocytes isolated from un-stimulated mice (Figure 3B–C).
Characterization of SAA expression in peripheral blood
monocytes
mRNA was isolated from monocytes from mice that developed
AA-amyloidosis after AEF and AgNO3-injections, mice that been
challenged with either AEF or AgNO3 48 hours prior to isolation
and untreated controls. PCR with SAA 3 specific primers
amplified a product with the expected size of 328 bp in all four
monocyte preparations (Figure 4). The SAA1 and SAA2 specific
primers did not amplify any product in any of the monocyte
preparations (Figure 4).
Discussion
We have shown that monocytes isolated from mice with AA
amyloid can carry AEF activity and lead to the development of AA
amyloidosis in a susceptible recipient. AA-amyloid was detected in
the spleen of 19 out of 48 (40%) mice from group H, after injection
with monocytes isolated from mice with AA amyloidosis, group G
(Table 2 and 3). There was a variability in the degree of transfer,
and amyloid did not develop in any mice from group H5 and H7
containing six and five mice, respectively, while amyloid developed
Table 5. Analysis of AEF activity in monocytes isolated at different time points after AEF and AgNO3 injection.
Treatment of mice prior to monocytes isolation Recipient mice
Group AEF AgNO3 Duration
No. of mice with
amyloid/total
no. of mice
Amyloid
grade Group
No. of mice with
amyloid/total no. of
mice
Amyloid
grade
K1 ++ 2 min 0/3 2 L1 0/9 2
K2 ++ 6 hours 0/3 2 L2 0/9 2
K3 ++ 48 hours 3/3 1+ L3 0/9 2
K4 ++ 7 days 3/3 2+ L4 5/9 1+
Mice in group K received an i.v. injection of 0.1 ml AEF with a sequential s.c. injection of 0.2 ml 1% silver nitrate and were sacrificed 2 minutes, 6 and 48 hours, and 7
days later. Peripheral blood monocytes were isolated, sonicated and injected in to new groups with three animals in each, group L. These mice received inflammatory
stimuli day 1, 7 and 14 and were sacrificed day 16. The presence of amyloid was analyzed in spleen after Congo red staining.
doi:10.1371/journal.pone.0003308.t005
Figure 2. (A) Flow cytometry analysis of isolated and cultured fraction of peripheral blood monocytic cells (PBMC). The measurements were
performed using forward scatter versus side scatter and 10,000 events were recorded. The marked area represents monocytic population and four
independent isolations were analyzed. The monocyte population was determined to 64%615% (mean6SD). Insert shows analysis of PBMC prior to
culture. (B) Representative picture of a cell recovered after isolation and culture. Bar 1 uM.
doi:10.1371/journal.pone.0003308.g002
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difference between groups most likely relates to technical problems
with monocyte preparations and does not reflect variations in
seeding efficiency. We used small volumes of blood (1 ml) for
isolation and the procedure involves gradient separation, multiple
washes and cell culture and at all these steps cells could be lost.
Monocytes account only for about 1–3% of the total number of
leukocytes in mouse [24] and we only detected AA/SAA reactivity
in 5% of the monocyte population (Figure 3A). Hence, if we
postulate that the absence of amyloid in H5 and H7 groups results
from poor monocyte preparations from G5 and G7 (Table 2 and
3), and only include groups with at least one positive mouse, AA-
amyloid was present in 19 out of 37 animals (51%). It was
previously shown by our group that AEF can be efficient in a low
dose as 15 pg protein [13]. AA-amyloidosis in group G mice was
accelerated by AEF injections and it may be argued that injected
AEF is transferred from these animals to group H mice. However,
the absence of amyloid in mice given plasma recovered from the
amyloid laden mice, group D or plasma recovered from mice
injected with AEF group E, opposes this possibility. So is also the
transfer of seeding activity from monocytes isolated from group
H2 mice. In the H2 group, five out of five mice developed AA
amyloidosis and monocytes recovered were injected into five new
groups, each containing three animals (J1–5). Here AA amyloid
appeared in all five groups and affected 80% of the animals
(Table 4). This transfer of seeding activity with monocytes isolated
from mice in the H groups to mice in the J groups did not involve
any AEF injection.
From where does the AA/SAA reactivity found in the
monocytes originate?
The antiserum used in this study was raised against mouse AA,
corresponding to residues1–76 of SAA1, and can not differentiate
between AA and SAA. Therefore we analysed the mRNA
expression of SAA 1, 2 and 3 in isolated cells. Only the non-
amyloidogenic SAA 3 mRNA was detected in monocytes, and its
expression occurred in all monocyte preparations studied,
independent of on ongoing inflammation or presence of amyloid
in the mouse (Figure 4). SAA 3 expression has earlier been shown
in monocytes/macrophages [25–27] so this finding is not
surprising. The members of the SAA family resemble each other
to a certain degree [8,28,29], but in the region 1–76 of SAA 1 and
SAA 3 there are 26 amino acid substitutions. This is a major
sequence difference and the absence of labelling of monocytes in
preparations from mice that received AgNO3 alone or untreated
mice show that there is no cross reactivity between the used
antibody and SAA 3. Instead, the immunolabeling and mRNA
expression pattern supports our hypothesis that the monocytes are
capable to phagocytose AA amyloid. This amyloid can thereafter
remain either intact or partly degraded in the lysosomes. We tried
but failed to show an unquestionable full co-localization of AA/
SAA reactivity and the lysosome specific marker LAMP-2 [30].
This may partly be due to the narrow cytoplasm of the monocytes,
but as visualised by confocal microscopy (figure 3A), the AA/SAA
reactivity is present all through the rim-like cytoplasm. These cells
were also stained for amyloid with Congo red, but no staining
could be detected. This is not unexpected since minute intra
lysosomal fibrilar deposits would escape detection, but still be
sufficient to exert AEF activity.
When and where is the amyloid engulfed by the
monocyte?
There was a need for a small amount of amyloid to be present in
the spleen before isolated monocytes could transfer AEF activity
and when animals had been given AEF an silver nitrate, amyloid
was not present at any other location at day seven. The site for
early amyloid deposition in the spleen is the perifollicular region,
Figure 3. Analysis of AA/SAA reactivity in peripheral blood monocytes by confocal microscopy showed immunoreactivity in 5% of
the monocytes isolated from a mouse with AA-amyloidosis (A). There was no reactivity present in monocytes recovered from a mouse given
one AgNO3 injection 48 hrs prior to isolation (B) or in monocytes isolated from untreated mice (C). The used rabbit antiserum recognizes both protein
AA and SAA and was visualized by goat anti rabbit Alexa488-cojugated IgG. Cell nuclei were labeled with TO-PRO3. Bar 10 um.
doi:10.1371/journal.pone.0003308.g003
Figure 4. SAA 1, SAA 2 and SAA 3 mRNA expression in
peripheral blood monocytes were analysed with PCR. Cells were
isolated from mice that developed AA-amyloid after AEF and AgNO3
injections or from mice that received AEF or AgNO3 injections only or
from untreated mice. Expression of the amyloid-prone SAA 1 or non-
amyloidogenic SAA 2 was absent in all monocyte preparations. SAA 3
mRNA was detected in all cells independent of treatment. Mouse liver
cDNA was used as a positive control. The PCR products were separated
on a 1.6% agarose gel.
doi:10.1371/journal.pone.0003308.g004
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large number of macrophages. These cells have been implicated in
amyloidogenesis based on their close ultrastructural relationship
with amyloid deposits [31,32], phagocytic function [33], and their
proteolytic enzymes [34]. This is the region where blood cells can
migrate in and out of the circulation and is in contact with the
splenic parenchyma, and a putative site where passing peripheral
blood monocytes could phagocytize AA-amyloid. It was shown
previously that AEF injected into a mouse kept its activity for at
least 180 days, and AA amyloid developed to the same extent
when AgNO3 injections were given [13]. This shows that the AEF
is stored in the organism and escapes degradation and clearance.
Monocytes reside in the circulation for a limited time and will
eventually migrate out to the peripheral organs where they
transform into macrophages or related cells [35]. At this location
they can stay for many years [36] and therefore may act as
reservoirs for AEF.
Transmission of amyloidosis has been shown also for murine
apolipoprotein AII (apoAII) amyloidosis [37]. The question can be
raised whether also other systemic and localized forms of
amyloidosis can be transmissible and whether this is possible in
humans. Transmissibility of AA-amyloidosis is not limited to mice
but has been demonstrated in hamster [38] and mink [22] and
there is no reason to believe that human is a protected species.
Iatrogenic transmission of AEF-activity through blood transfusion,
similar to what has been shown for variant Creutzfeldt-Jakob’s
disease [39] can be possible, given that the recipient has a chronic
inflammatory disease. It is interesting to note that Brown et al [40]
showed prion infectivity of blood from mice clinically ill after
inoculation with human transmissible spongiform encephalopathy.
Although the degree of transmissibility was low they detected the
highest infectivity with the buffy coat while that of plasma and
Cohn fractions were lower. This is in agreement with our finding
and points to cells as seed carrier and disease primers.
Materials and Methods
Animals
Outbreed female 6–8 weeks old NMRI mice (B &K Universal;
So ¨derta ¨lje, Sweden), were housed individually and had free access
to water and standard chow diet (R70 pellets, Lactamin, Vadstena,
Sweden). The study was approved by the Animal Ethics
Committee, Linko ¨ping University, Sweden.
Induction of amyloidosis
AEF was extracted from amyloid-laden liver as described earlier
[13], and used for amyloid induction in four different groups of
mice. Each mouse received 20 mg of protein extract as an
intravenous injection in the tail vein. This is further on referred to
as AEF-injection. When plasma or peripheral blood monocytes
were examined for their ability to transfer AEF activity, sonication
3620 sec at 23 kHz (MSE Soniprep 150, SANYO, UK) was
performed at the time for injection, and a volume of 0.1 ml was
injected in the tail vein. The inflammatory challenge was, in all
groups, induced by 0.2 ml 1% silver nitrate (AgNO3) given as
multiple injections subcutaneously.
Experimental design for plasma analysis
Thirty animals were divided into three groups (A–C). Animals
in group A received AEF and 0.2 ml 1% AgNO3 on day 1 and
additional AgNO3 injections on day 7 and 14; animals in group B
received AEF only; and animals in group C were untreated.
Plasma and spleen were collected when the animals were sacrificed
on day 16. Approximately 1 ml of blood was collected from each
mouse in heparinized tubes, and plasma was recovered after
centrifugation 10 min/2000 rpm/4uC (Allegra X-12R, Beckman,
CA, USA). All plasma samples recovered from mice in group A
and B were each reinjected into two new animals (group D and E,
respectively) (Table 1). Plasma samples recovered from group C
were each injected into a single new animal (group F) (Table 1). All
these mice (D–F) received 0.2 ml of 1% AgNO3 on day 1, 7 and
14 and were sacrificed day 16. The presence of amyloid was
investigated in spleen sections after Congo red staining.
Experimental design for peripheral blood monocyte
analysis
Nine mice (group G) received AEF and 0.2 ml 1% AgNO3 on
day 1 and further AgNO3 injections on day 7, 14, 21 and 28. The
animals were sacrificed on day 35 and the presence of extensive
amyloid was verified in spleen sections after Congo red staining. At
the same time blood was collected and monocytes were isolated as
described below. These nine isolates were sonicated and their AEF-
activity was tested in 9 groups (H1–9) with 5–8 mice in each group
(Table 2). In addition to the sonicated monocytes on day 1, animals
in groups H1–8 received 0.2 ml of 1% AgNO3 on day 1, 7 and 14
while animals in group H9 did not receive any inflammatory
challenge. Group H10 received sonicated monocytes isolated from
untreated mice and 0.2 ml of 1% AgNO3 on day 1, 7 and 14. All
animals were sacrificed on day 16. Blood was collected and the
presence of amyloid was investigated in sections from spleen after
Congo red staining. Group H2 contained five mice which all
developed amyloid (Table 3), and monocytes isolated from these
were sonicated and injected into five new groups (J1–5) (Table 4),
each containing three animals, together with 0.2 ml of 1% AgNO3
on day 1, 7 and 14. The presence of amyloid was investigated in
sections from spleen after Congo red staining.
To study the connection between amyloid load and transmis-
sibility, twelve animals (groups K1–4) received AEF and a single
injection of 0.2 ml of 1% AgNO3 (Table 5). Thereafter, animals
were sacrificed in groups of three mice at time points 2 minutes
(K1), 6 hours (K2), 48 hours (K3) and 7 days post-injection (K4).
Blood and spleen was collected when the animals were sacrificed.
Monocytes isolated from mice in groups K1–K4 were each
injected into three new animals (36 mice), groups L1–L4. These
animals were also given 0.2 ml of 1% AgNO3 day 1, 7 and 14 and
sacrificed on day 16. Spleen was recovered and the presence of
amyloid was analysed in sections after Congo red staining.
Isolation of peripheral blood monocytes
Approximately 1 ml of blood was collected from each mouse in
heparinized tubes, diluted 1:1 with 0.9% NaCl solution and
overlaid (1:1) on Ficoll-Paque
TM Premium gradient (GE Health-
care Bio-Sciences AB, Uppsala, Sweden) and centrifuged 40 min/
4006g/16uC (Allegra X-12R centrifuge). Peripheral blood
mononuclear cells were recovered and remaining erythrocytes
were lysed with ice cold water. Cells were incubated in RPMI-
1640 medium (Sigma Aldrich, Stockholm, Sweden) supplemented
with 10% fetal calf serum at 37uC in an atmosphere of 5% CO2
over night. Non-adherent cells were rinsed of and adherent cells
were released by trypsination and pelleted (10 min/1006g). Cells
analysed for AEF-activity were resuspended in 3 ml of sterile water
and stored at 4uC, until used.
Flow cytometry
Isolated cells from untreated mice were fixed in 4% parafor-
maldehyde (PFA), pH 7.4 for 15 min at 4uC and resuspended in
PBS. Flow cytometry was carried out on four independent
Transfer of AA Amyloidosis
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Monocytes were identified based on their forward scatter versus
side scatter, and 10,000 events were recorded.
Histology
Spleen was fixed in 10% neutral buffered formalin and
embedded in paraffin. The presence of amyloid was investigated
in 10 um thick sections after Congo red staining [41] and the
amyloid amount was quantified according to the following scale: 0;
absent; 1+ trace of amyloid; 2+ small amyloid deposits; 3+
moderate amyloid deposits; 4+ extensive amounts of amyloid [13].
Confocal microscopy
Isolated monocytes were fixed in 4% PFA, pH 7.4 for 20 min at
4uC and used for cytospin preparation by centrifugation (3 min,
500 rpm; Cytospin3 cytocentrifuge, Shandon, UK). Cells were
incubated with antibodies raised against mouse amyloid protein A
at a dilution 1:200 over night, at 4uC. This in house produced
rabbit antiserum recognizes both AA and SAA. The immunore-
activity was visualized with goat anti-rabbit IgG – Alexa Fluor 488
(Molecular Probes, Eugene, OR, USA) diluted 1:1000, 2 hrs at
room temperature. Incubations and washing steps were performed
in the presence of 0.1% Saponine in BSS buffer (137 mmol/l
NaCl, 5.36 mmol/l KCl, 1.26 mmol/l CaCl2, 811 mmol/l
MgSO4, 441 mmol/l KH2PO4, 1.4 mmol/l Na2HPO4). Slides
were mounted with glycerol/PBS (1:1) in the presence of nuclear
stain TO-PRO-3 (Molecular Probes). Cells were examined with a
Nikon eclipse E600 microscope connected to a Nikon C1 confocal
unit with argon 488 and HeNe 543 lasers (Nikon, Kawasaki,
Japan). Digital pictures were taken with an EZ-C1 digital camera
and software version 1.0 for Nikon C1 confocal microscopy.
Electron microscopy
Cells were fixed in 2% PFA with 0.25% glutaraldehyde in PBS
for 1 h, post-fixed in 1% OsO4 and embedded in Epon (Ladd
Research Industries, Burlington, VT, USA). The material was
studied at 100 kV in a Jeol 1230 electron microscope (Jeol,
Akishima, Tokyo, Japan). Electron micrographs were taken with a
Gatan multiscan camera model 791 with Gatan digital micro-
graph software version 3.6.4 (Gatan, Pleasanton, CA, USA).
Characterization of SAA expression in peripheral blood
monocytes
mRNA was isolated from peripheral blood monocytes (Quick-
Prep
TM Micro mRNA purification kit, GE Healthcare, Sweden)
and 20 ml of the reaction mixture was used for first-strand DNA
synthesis (First-Strand cDNA Synthesis kit, Amersham Bioscienc-
es, Sweden). SAA1-3 expression was analysed by PCR with the
following primer sequences: SAA 1: forward primer
59GAAGCTGGCTGGAAAGATG and reverse primer
59GCTTTCAGGAATTCTTCGG (NM_011314); SAA 2: for-
ward primer 59GGAGGGTTTTTTTCATTTGTTC and re-
verse primer 59TGCTGACCAGGAAGCCAA (NM_009117) and
SAA3: forward primer 59GCCTTCCATTGCCATCATT and
reverse primer 59AGTGGCAAAGACCCCAAC (BC055885).
The PCR was performed with 5 ml of the first-strand DNA
preparation and 10 mmol/l of each primer under the conditions:
denaturation 95uC for 30 sec, annealing 45uC for 30 sec, and
elongation 72uC for 1 min for 33 cycles. Mouse liver cDNA was
used as positive control. The products were analyzed on 1.6%
agarose gel and visualized with Gel Doc
TM XR gel documentation
system (Bio-Rad, Milan, Italy).
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